Dr Vivek Jha, Head – R&D, Cilicant & Mr Dhairy Sharma, Manager – Business Development (Healthcare Division), Cilicant

Speakers in this video:
Dr Vivek Jha, Head – R&D, Cilicant & Mr Dhairy Sharma, Manager – Business Development (Healthcare Division), Cilicant

Topic: Can FREXIL minimise nitrosamine risk? Let’s discuss

Key Highlights:
[1] Nitrosamines remain a major risk as they can enter during manufacturing or form later in the finished drug product.

[2] FREXIL works through proactive suppression to stop nitrosamine formation at the molecular level before it begins.

[3] The dual action technology helps strengthen regulatory compliance while protecting patient safety and product stability.